JPRN-UMIN000014351已完成2 期
Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer. - Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)cardiac dysfunction 2)severe complication(uncontoroled DM, hypertension, renal failure, hepatic failure, severe infection, mental disorder) 3)pregnancy, lactation 4)double cancer 5)bilateral breast cancer 6)pulmonary fibrosis, interstitial pneumonia 7)allergy 8)neuropathy 9)HBs antigen positive
研究者
相似试验
已完成
2 期
Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancerBreast cancerJPRN-UMIN000014163ational Cancer Center Hospital43
已完成
2 期
Phase II study of neoadjuvant treatment with Exemestane for 24 weeks in postmenopausal women with hormone receptor positive Stage II or IIIA breast cancer.Breast CancerJPRN-C000000345Japanese Foundation for Multidisciplinary Treatment of Cancer110
进行中（未招募）
2 期
eoadjuvant bevacizumab and temozolomide chemotherapy for malignant gliomaJPRN-jRCT1031180233Tamura Ryota15
未知
2 期
An exploratory phase II study of neoadjuvant bevacizumab and temozolomide chemotherapy for patients with newly diagnosed malignant gliomamalignant gliomaJPRN-UMIN000025579Keio university school of medicine15
招募中
2 期
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancerBreast cancerJPRN-UMIN000013886Tokyo Women's Medical University30